Solomon Moshkevich Sells 4,692 Shares of Natera (NASDAQ:NTRA) Stock

by · The Markets Daily

Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 4,692 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92. Following the completion of the sale, the insider owned 113,065 shares of the company’s stock, valued at $26,090,879.40. This trade represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Solomon Moshkevich also recently made the following trade(s):

  • On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total value of $714,450.00.
  • On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $198.60, for a total value of $595,800.00.
  • On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total transaction of $229,369.08.
  • On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $193,858.56.
  • On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The stock was sold at an average price of $187.95, for a total transaction of $54,881.40.
  • On Wednesday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $159.99, for a total transaction of $479,970.00.

Natera Trading Down 0.8%

NTRA opened at $225.49 on Thursday. The stock has a market capitalization of $31.19 billion, a P/E ratio of -98.47 and a beta of 1.63. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $246.90. The firm’s fifty day simple moving average is $210.11 and its 200 day simple moving average is $178.07.

Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.26) EPS. On average, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

NTRA has been the subject of a number of recent research reports. Wells Fargo & Company upped their price target on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research report on Monday. JPMorgan Chase & Co. increased their target price on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday. Morgan Stanley lifted their price target on shares of Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Piper Sandler increased their price objective on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Finally, Zacks Research downgraded Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Fifteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $229.12.

Get Our Latest Research Report on NTRA

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NTRA. Siemens Fonds Invest GmbH lifted its position in shares of Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after purchasing an additional 54 shares during the period. Guided Capital Wealth Management LLC lifted its holdings in Natera by 0.5% in the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after buying an additional 66 shares during the period. BOKF NA boosted its position in Natera by 1.9% during the 3rd quarter. BOKF NA now owns 3,733 shares of the medical research company’s stock valued at $601,000 after acquiring an additional 69 shares in the last quarter. Silvant Capital Management LLC grew its holdings in shares of Natera by 0.5% during the 3rd quarter. Silvant Capital Management LLC now owns 13,488 shares of the medical research company’s stock worth $2,171,000 after acquiring an additional 70 shares during the period. Finally, Main Management ETF Advisors LLC raised its position in shares of Natera by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $743,000 after acquiring an additional 72 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Recommended Stories